Hyundai Pharm Signs AI Drug Development Agreement with Paminogen

[Asia Economy Reporter Lee Chun-hee] Hyundai Pharm announced on the 20th that it has signed an AI drug development agreement with PaminoGen, an AI deep learning-based new drug development specialist company.

PaminoGen is discovering various compound drugs through the 'LuciNet' platform, built on AI and quantum chemistry-based software and bio big data. LuciNet consists of 'LuciNet GaiaDB,' which includes 20 billion compound data worldwide and biological information such as disease genes and proteins; the AI deep learning anticancer drug discovery platform 'LuciNet Onco'; the signal transduction protein prediction platform 'LuciNet Kinase'; and 'LuciNet Meta,' which predicts the metabolic state of drugs in vivo. Drugs explored through this AI deep learning technology are developed into lead candidates capable of entering preclinical stages within six months through precise predictive calculations based on quantum chemistry.

Hyundai Pharm expects that by utilizing PaminoGen's deep learning platform, it will be possible to predict the in vivo properties and toxicity of new chemical substances in a short time, enabling more efficient derivation of new drug candidates. It also anticipates a revolutionary reduction in drug development time and cost compared to the existing new drug development process.

Kim Sung-heon, Vice President of New Drug Research Headquarters at Hyundai Pharm, said, "Through joint research with PaminoGen, we expect to enhance Hyundai Pharm's new drug development capabilities and enable early candidate discovery," adding, "We plan to take a step further in research and development aligned with global trends."

This content was produced with the assistance of AI translation services.